Zoetis Inc. News
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
see moreZoetis Inc. Market News
1h
Zoetis Shares Rally After UBS, Morgan Stanley Adjust Price Targets Ahead of Q3 Results
- Zoetis (ZTS) stock jumps ~7.5% following price target adjustments from UBS and Morgan Stanley, as investors await Q3 earnings and FDA‑approved Convenia RTU.
8d
Zoetis Gains FDA Nod for Single-Shot Canine Antibiotic Amid Analyst Downgrade and Dividend Declaration
Zoetis (ZTS) received FDA approval for Convenia RTU for dogs on October 20, 2026—injected antibiotic—with a dividend declared and analyst downgrades shifting views.
15d
Zoetis Names Iris Knobloch to Board as Q4 Dividend Declared—Key Corporate Moves in October 2026
Zoetis appoints Iris Knobloch to its board effective December 1 and declares a $0.53 Q4 dividend, offering context to ZTS at $79.59 on October 19.
22d
Zoetis Enhances Diagnostics Portfolio with VitalRADS Acquisition and Vetscan Opticell™ Expansion
Zoetis this week bolstered its diagnostics capabilities by completing the VitalRADS teleradiology acquisition and expanding Vetscan Opticell™ functionality, strengthening its position in diagnostic services.
29d
Zoetis Expands Equine Diagnostics with Vetscan Enhancements as Q3 2026 Earnings Approaches
Zoetis is adding equine-specific hematology features to its Vetscan platforms ahead of its Q3 earnings webcast on November 5, strengthening its diagnostics edge.
